Business

Biotech, pharma, and money in science

Ginkgo Bioworks 06
Biotech

Ginkgo Bioworks scores an eye-popping valuation with latest fundraise

By Jonathan Saltzman — Boston Globe

Business

Martin Shkreli’s drug company is losing money — and its salesforce feels cheated

By Adam Feuerstein

Christopher Reeve and his wife Dana
Business

Reeve Foundation to invest in paralysis-treatment companies, as more nonprofits act like VCs

By Rebecca Robbins

CVS/Aetna
Business

Former CVS head’s gift will bolster neuroscience research at University of Rhode Island

By Edward Fitzpatrick — Boston Globe

Health Tech

Former Athenahealth CEO Jonathan Bush joins health care startup

By Jon Chesto — Boston Globe

Purdue Pharma headquarters
Business

Purdue Pharma filed for bankruptcy. What does it mean for lawsuits against the opioid manufacturer?

By Andrew Joseph

Purdue Pharma headquarters
Business

Purdue Pharma, maker of OxyContin and other drugs, files for bankruptcy

By Andrew Joseph

Peanuts on red background
Biotech

FDA advisory panel recommends approval of Aimmune peanut allergy therapy

By Adam Feuerstein

MODERNA - Norwood facility
Biotech

With some safety caveats, new Moderna data show mRNA can teach the body to make its own medicine

By Adam Feuerstein

Joel S. Marcus
Pharmalot

Judge dismisses real estate tycoon’s lawsuit against his son

By Jonathan Saltzman — Boston Globe

Biotech

Did a biotech exec crib a New Yorker cartoon?

By Jonathan Saltzman — Boston Globe

Play
Business

Watch: Direct-to-consumer drug advertising, explained

By Damian Garde

Peanut butter
Biotech

7 things to know about Aimmune’s peanut allergy therapy ahead of a pivotal FDA meeting

By Adam Feuerstein

Pfizer R&D illo
Business

Pfizer’s chessmaster: How a top scientist helped invigorate a lumbering drug giant

By Matthew Herper

Eli Lilly insulin
Business

Reining in drug spending: What states can learn from one another

By Priyanka Dayal McCluskey — Boston Globe

Biotech

New Sanofi CEO wants to tap digital technology to improve drug research and sales

By Matthew Herper

Pharmalot

Pharmalittle: Hormone therapy link to breast cancer strengthened; where did Sacklers’ Purdue money end up?

By Elizabeth Cooney

Broad Institute signage
Business

Battleground narrowed in CRISPR patent case between University of California and Broad

By Sharon Begley

Biotech

Celgene sells psoriasis pill to Amgen for $13.4 billion, clearing way for close of Bristol merger

By Adam Feuerstein

Cambridge: Sarepta
Biotech

Sarepta stumbles on FDA rejection of a new drug to treat Duchenne muscular dystrophy

By Adam Feuerstein

STAT SPOTLIGHT
Biotech

Can targeting one protein complex solve multiple diseases? NodThera is betting on it

By Diana Cai

Sarepta - Cambridge -AP
Biotech

As Sarepta awaits approval of new Duchenne drug, big questions hang over therapy already on market

By Adam Feuerstein

Jeffrey Leiden
Biotech

Vertex, known for cystic fibrosis drugs, sets its sights on taming pain

By Jonathan Saltzman — Boston Globe

Marisa Boidi
Biotech

Toddler denied $2.1m gene therapy will now get it for free

By Jonathan Saltzman — Boston Globe

Pharmalot

Pharmalittle: Delayed approval decision raises fears for Vascepa; drug prices snakebit by lack of competition

By Elizabeth Cooney

Vascepa pill handout
Biotech

Amarin now says FDA plans outside panel review of its Vascepa heart drug, delaying approval decision

By Adam Feuerstein

Pharmalot

Pharmalittle: Medicare will cover CAR-T; Trump health care overhaul in the wings

By Elizabeth Cooney

Pharmalot

Pharmalittle: A new scandal for Novartis; opioid distributors offer to settle lawsuits

By Elizabeth Cooney

Pharmalot

Pharmalittle: Pay-to-play clinical trials draw scrutiny; Chinese drug ingredients called U.S. threat

By Elizabeth Cooney

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy